摘要
目的:探讨ABCG2及CD133蛋白在宫颈癌的表达及临床意义。方法:用免疫组化SP法检测92例宫颈癌、40例宫颈上皮内瘤变(CIN)和30例正常宫颈组织中AB-CG2及CD133蛋白的表达。结果:ABCG2在宫颈癌、CIN和正常宫颈组织的阳性表达率分别为69.6%、42.5%、23.3%,CD133为57.6%、37.5%、23.3%,两者在宫颈癌的表达均高于CIN及正常组织,差异均有统计学意义(P<0.05);两者表达与宫颈癌患者年龄、肿瘤大小、临床分期无相关性(P>0.05),而在不同分化组间表达的差异有统计学意义(P<0.05)。结论:ABCG2和CD133蛋白异常表达与宫颈癌的发生、发展有关,二者联合检测可作为评估宫颈癌恶性程度、指导治疗的重要参考指标。
Objective：To explore the expression and clinical significance of ABCG2 and CD133 protein in cervical cancer.Methods：SP immunohistochemical technique was used to detect the expression of ABCG2 and CD133 protein in 92 cases of cervical cancer,40 cases of CIN,and 30 cases of normal cervical tissue.Results：The positive rates of ABCG2 in cervical cancer,CIN,normal cervical tissue were 69.6%,42.5%,23.3%,respectively.The positive rates of CD133 were 57.6%,37.5%,23.3%,respectively.The expressions of ABCG2 and CD133 were both significantly higher in cancer group than that in CIN and normal group（P〈0.05）.In cervical cancer group,there were no significant differences for ABCG2 and CD133 expression in different age patient groups,and there was no difference among different tumor size,and clinical stages,however,there was significant difference among different pathological grades（P〈0.05）.Conclusion：The increased expression of ABCG2 and CD133 protein may correlate with the occurrence and devel opment of cervical cancer.The combined detection of ABCG2 and CD133 may be an important index to evaluating the degree of malignance and guiding clinical treatment of cervical cancer.
出处
《现代妇产科进展》
CSCD
北大核心
2010年第2期115-118,共4页
Progress in Obstetrics and Gynecology
基金
教育部新世纪优秀人才支持计划(No:NCET-07-0403)资助
